Literature DB >> 33395587

The Effect of Delay in Care among Patients Requiring Intravitreal Injections.

Weilin Song1, Rishi P Singh2, Aleksandra V Rachitskaya3.   

Abstract

PURPOSE: To examine the effect of delay in care on visual acuity (VA) in patients requiring intravitreal injections (IVIs).
DESIGN: Retrospective cohort study. PARTICIPANTS: Patients 18 years of age or older with diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), or both; neovascular age-related macular degeneration (nAMD); or retinal vein occlusion (RVO) scheduled to see a retina specialist during the mandated lockdown period (March 14 - May 4, 2020 [the coronavirus disease 2019 period]) and who had received an IVI in the 12 weeks prior.
METHODS: Chart review was performed and demographics, diagnoses, procedures, and VA were recorded. MAIN OUTCOME MEASURES: VA in patients who completed, canceled, and no-showed for the scheduled visit.
RESULTS: Of the 1041 total patients, 620 (60%) completed the scheduled visit, whereas 376 (36%) canceled and 45 (4%) no-showed. In patients who missed the visit, the average delay in care was 5.34 weeks. In those who missed a visit, VA was assessed at the subsequent visit. Patients who canceled a visit were older, and patients who no-showed had lower baseline vision (mean Early Treatment Diabetic Retinopathy Study letters ± standard error [SE]: no-show, 53.27 ± 3.21 letters; canceled, 60.79 ± 1.11 letters; and completed, 62.81 ± 0.84 letters; P = 0.0101) and were more likely to have DME, PDR, or both (no-show, 13 patients [29%]; canceled, 56 patients [16%]; completed, 81 patients [13%]; P = 0.0456). Patients who missed a visit lost vision as compared with the patients who completed one (no-show, -5.024 ± 1.88 letters; canceled, -1.633 ± 0.65 letters; completed, 0.373 ± 0.50 letters; P = 0.0028). Patients with DME, PDR, or both (-3.48 ± 1.95 letters vs. 2.71 ± 1.75 letters; P = 0.0203), with RVO (-3.22 ± 1.41 letters vs. 0.95 ± 1.23 letters; P = 0.0230), and, to lesser degree, with nAMD (-1.23 ± 0.70 letters vs. -0.24 ± 0.56 letters; P = 0.2679) lost vision compared with patients with same diagnoses who completed the scheduled visit.
CONCLUSIONS: In patients requiring IVIs, a delay in care of 5.34 weeks resulted in vision loss. It was seen in all patients, but was more prominent in patients with DME, PDR or both and RVO. Further studies are necessary to examine whether these vision changes persist over a longer duration.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  COVID-19 pandemic; Delays in care; Intravitreal injections; Nonadherence

Year:  2021        PMID: 33395587     DOI: 10.1016/j.oret.2020.12.020

Source DB:  PubMed          Journal:  Ophthalmol Retina        ISSN: 2468-6530


  15 in total

Review 1.  Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare.

Authors:  Ella H Leung; Jason Fan; Harry W Flynn; Thomas A Albini
Journal:  Clin Ophthalmol       Date:  2022-01-04

2.  Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration.

Authors:  Joel Hanhart; Rony Wiener; Hashem Totah; Evgeny Gelman; Yishay Weill; Adi Abulafia; David Zadok
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-01-11       Impact factor: 3.535

Review 3.  The Impact of COVID-19 on Diabetic Retinopathy Monitoring and Treatment.

Authors:  Ishrat Ahmed; T Y Alvin Liu
Journal:  Curr Diab Rep       Date:  2021-09-08       Impact factor: 4.810

4.  The Utilization of Phone Communication with Patient Companions During a Pandemic.

Authors:  Weilin Song; Aleksandra V Rachitskaya
Journal:  J Patient Exp       Date:  2021-12-08

5.  Effect of COVID-19 Pandemic on Presentation of Patients With Diabetic Retinopathy in a Multitier Ophthalmology Network in India.

Authors:  Anthony V Das; Raja Narayanan; Padmaja K Rani
Journal:  Cureus       Date:  2021-10-30

6.  The ophthalmic surgical backlog associated with the COVID-19 pandemic: a population-based and microsimulation modelling study.

Authors:  Tina Felfeli; Raphael Ximenes; David M J Naimark; Philip L Hooper; Robert J Campbell; Sherif R El-Defrawy; Beate Sander
Journal:  CMAJ Open       Date:  2021-11-23

7.  A model to quantify the influence of treatment patterns and optimize outcomes in nAMD.

Authors:  Andreas Clemens; Benjamin Gmeiner; Focke Ziemssen; Hansjürgen Agostini; Nicolas Feltgen; Robert P Finger; Christos Haritoglou; Hans Hoerauf; Matthias Iwersen; Martina Porstner
Journal:  Sci Rep       Date:  2022-02-18       Impact factor: 4.379

8.  Short- and Long-Term Visual Outcomes in Patients Receiving Intravitreal Injections: The Impact of the Coronavirus 2019 Disease (COVID-19)-Related Lockdown.

Authors:  Vivian Paraskevi Douglas; Konstantinos A A Douglas; Demetrios G Vavvas; Joan W Miller; John B Miller
Journal:  J Clin Med       Date:  2022-04-08       Impact factor: 4.964

9.  Management of acute proliferative diabetic retinopathy related complications during the first COVID-19 wave.

Authors:  Niku Dhillon; Cynthia Santiago
Journal:  BMC Ophthalmol       Date:  2022-03-12       Impact factor: 2.209

10.  Economic Impact of COVID-19 Lockdown on Italian NHS: Focus on Diabetes Mellitus.

Authors:  Enrico Torre; Giorgio Lorenzo Colombo; Sergio Di Matteo; Chiara Martinotti; Maria Chiara Valentino; Alberto Rebora; Francesca Cecoli; Eleonora Monti; Marco Galimberti; Paolo Di Bartolo; Germano Gaggioli; Giacomo Matteo Bruno
Journal:  Clinicoecon Outcomes Res       Date:  2021-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.